Abiopharma

New Form 424B3 - Autolus Therapeutics plc Filed: 2026-01-12 AccNo: 0001730463-26-000013 Size: 117 KB

(90% Positive) ADC Therapeutics SA (ADCT) Announces Enrollment Update for contained Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(85% Positive) Gemini Therapeutics Inc. (the company became a subdivision of the company Disc Medicine (NASDAQ : IRON)) (GMTX) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Regulatory Process, Efficacy Assessment

(90% Positive) Autolus Therapeutics plc (AUTL) Announces Clinical Development Update

(90% Positive) Moleculin Biotech Inc. (MBRX) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

(90% Positive) Nurix Therapeutics Inc (NRIX) Files Form 8-K

(90% Positive) Acumen Pharmaceuticals Inc (ABOS) Announces Clinical Development Update

(99% Positive) Clearpoint Neuro Inc (CLPT) Announces Clinical Development Update

(90% Positive) Prime Medicine Inc (PRME) Files Form 8-K

(99% Neutral) Myriad Genetics Inc (MYGN) Announces Business Combination

(99% Positive) Outset Medical Inc. (OM) Reports Q1 2026 Financial Results

Vicarious Surgical Inc. - Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue